Orexo Ab · OMXSTO:ORX
Orexo Ab — Pareto Securities 16th Annual HC Conference 2025
17 slides from Orexo Ab's conference presentation, Sep 16, 2025
Slide 1: A commercial-stage pharma company developing drugs through cutting-edge drug delivery technologies
A commercial-stage pharma company, developing drugs through cutting-edge drug delivery technologies Sep. 16th, 2025
Slide 2: Legal disclaimer
2 Legal disclaimer • This presentation, which is personal to the recipient, has been prepared and produced by Orexo AB (publ) (“Orexo”) solely for the benefit of investment analysis and may not be used for any purpose other than assessment of investments concerning Orexo. Unless otherwise stated, Or
Slide 3: Orexo in brief
3 Orexo in brief Comments Q2 Strong cash generation Net Revenue LTM 1 from lead product 30 years of experience Addresses unmet needs developing improved within opioid use disorder SEK m 5.850 pharmaceuticals based on (OUD) and other areas proprietary drug delivery where our technologies can technolo
Slide 4: Commercial products and development pipeline
4 Commercial products and development pipeline Approved and/or Launched Product or Project/Indication/Technology Partners Exploratory Preclinical Clinical development phases Registration US EU RoW Zubsolv® Opioid Use Disorder (OUD) / Sublingual platform Commercial Abstral® Breaktrough Cancer Pain /
Slide 5: AmorphOX®
AmorphOX® The next-generation drug delivery technology unlocks a broad range of new opportunities in the development of innovative drugs
Slide 6: AmorphOX® is a unique drug delivery technology
6 AmorphOX® is a unique drug delivery technology The challenge AmorphOX unique strengths Amorphous materials, commonly used in drug development, are rapidly absorbed but tend to be unstable limiting routes of administration, distribution and storage 1 AmorphOX unique properties ensure physical and c
Slide 7: The scalable AmorphOX® platform takes Orexo beyond the OUD treatment area
7 The scalable AmorphOX® platform takes Orexo beyond the OUD treatment area Small Molecular weight (Mw) Large Small molecules Peptides Biologics Apomorphine Olanzapine Eletriptan Cetrorelix Semaglutide Enzyme Virus like Attenuated particle Virus Retained titer levels, Retained structure after Retain
Slide 8: AmorphOX® strategy focuses on large molecules and intranasal rescue medications
8 AmorphOX® strategy focuses on large molecules and intranasal rescue medications Progess internal • Izipry (OX124) targeting opioid overdose rescue • OX640 aimed at treating anaphylaxis medication • OX390 focused on overdoses from illicit drugs projects • OX125 for opioid overdose (currently paused
Slide 9: Izipry (registration phase) – powder-based intranasal rescue medication for opioid overdose
9 Izipry (registration phase) – powder-based intranasal rescue medication for opioid overdose • Izipry, formulated with AmorphOX®, is designed to combat overdoses from synthetic opioids, which make up more than 90% of opioid overdose incidents. • Izipry includes naloxone in a powder form, enhancing
Slide 10: OX640 (clinical phase) – emergency treatment of allergic reactions, incl. anaphylaxis
10 OX640 (clinical phase) – emergency treatment of allergic reactions, incl. anaphylaxis Rescue drugglobal Epinephrine market Growth rate CAGR • First line treatment today: intramuscular auto-injectors. In in the US (USD) market size 2024 (USD) 1 2024-2032 1 2024 the first nasal product was approved
Slide 11: OX640-002: Clinical study in subjects with and without allergic rhinitis
11 OX640-002: Clinical study in subjects with and without allergic rhinitis • Second clinical study with OX640, performed in subjects with and without allergic rhinitis (N=30)1 • The study suggest the following: • Commercial dose identified • Relevant plasma levels and pharmacodynamic effects2 for t
Slide 12: Early stage projects: AmorphOX® and large molecules
12 Early stage projects: AmorphOX® and large molecules In-vivo proof-of-concept study of nasal powder In-vivo proof-of-concept study of vaccine performed in collab. with Abera Bioscience nasal semaglutide powders IgG Serum 1,6 1,4 AmorphOX formulations Antibody response 1,2 1 Oral tablet 0,8 0,6 0,4
Slide 13: Financial & legal
13 Financial & legal 13
Slide 14: YTD 2025: Full-year financial forecast confirmed, incl. achieving positive EBITDA in 2025
14 YTD 2025: Full-year financial forecast confirmed, incl. achieving positive EBITDA in 2025 Income statement Jan-Jun Jan-Jun FY FY Comments Q2 SEK m 2025 2024 2024 2023 YTD 2025 developments & legal update ✓ Zubsolv US NR impacted negatively by a non-recurring rebate Net revenues (NR) 264.5 293.2 5
Slide 15: Future value drivers
15 Future value drivers
Slide 16: Approach for expansion
Q 2 2 0 2 5 P R E S E N TAT I O N 16 Approach for expansion Maintain Zubsolv® revenue streams in USD Growing revenues & Obtain FDA approval and initiate US launch of Izipry profit contributions Achieve milestones and receive royalties from existing and upcoming partnered products. Improving
Slide 17: Thanks
17 Thanks Thanks www.orexo.com www.orexo.com
Orexo — Pareto Securities 16th Annual HC Conference 2025 on 6ix